When a vaccine is inhaled, the body’s immune system responds in a different way that may be better at preventing infection compared to the traditional injected vaccines.

This new vaccine, named ChAd-triCoV/Mac, targets three different proteins in the SARS CoV-2 virus to improve the vaccine’s ability to protect against new strains (or variants) of the COVID virus. 

The AeroVax Trial is a Phase 2 clinical trial funded by the Canadian Institutes of Health Research (CIHR), Canada’s federal funding agency for health research. 

The AeroVax Trial will evaluate if this new COVID-19 vaccine is safe to give by inhalation (breathing it in) to people who have been vaccinated with at least three doses of a COVID mRNA vaccine. The researchers also want to look at how the body’s immune system responds to this vaccine. Participants will be randomly assigned to receive either the study vaccine or a placebo. 

A placebo is an inactive substance that doesn’t have any therapeutic effect. Placebos are used by researchers to compare to an active substance to see if the active substance is having any effect or causing any side effects. 

We will be enrolling approximately 350 participants across three sites in Canada: